Fundraising Fox
Calderatx
5 known investors
Find your way into Calderatx
Sign up to see every warm intro you have to Calderatx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Calderatx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases. Its lead candidate is in a Phase 1 healthy volunteer trial.
Founders & leadership
PT
Praveen TipirneniChief Executive Officer
LW
Liangsu WangChief Scientific Officer
ZL
Zhong LiuChief Technology Officer
AP
Aaron PeltaChief Business Officer
CW
Colm WhiteChief Program Officer
Investors · 5
Atlas Venture✓ confirmed by CalderatxCambridge · $500K – $1M
How we know: Atlas Venture's portfolio page · the company's own site · Not right? Tell us
Janus Henderson Investors✓ confirmed by CalderatxLondon
How we know: the company's own site · Not right? Tell us
LAV✓ confirmed by CalderatxHong Kong · $5M – $15M
How we know: the company's own site · Not right? Tell us
venBio Partnerslisted by venBio PartnersSan Francisco
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Calderatx do?
- Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases. Its lead candidate is in a Phase 1 healthy volunteer trial.
- Who are Calderatx's investors?
- Calderatx's investors include Atlas Venture, Janus Henderson Investors, LAV, venBio Partners, Wellington Management.